Regulatory Lilly plans Q1 2027 filing for obesity triple retatrutide PharmaphorumArmed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.Metabolic & GLP-1Read full story pharminent July 23, 2026 (Last updated: July 23, 2026) Pharmaphorum Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year. Metabolic & GLP-1 Read full story Post navigation Previous: GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugNext: Lilly’s Retatrutide Hits 22.6% Weight Loss in Phase 3, But Cardiovascular Benefit Remains Elusive Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026